Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL015
MIFTS: 48

Oral Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oral Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 77 54 15 17
Squamous Cell Carcinoma of Mouth 74
Mouth Squamous Cell Carcinoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050866
UMLS 74 C0585362
Sources

Summaries for Oral Squamous Cell Carcinoma

About this section
Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and melanoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Edetic Acid and Pentetic acid have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and bone.

Wikipedia : 77 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Sources

Related Diseases for Oral Squamous Cell Carcinoma

About this section

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.3 CCAT2 FOXCUT H19 HOTAIR MALAT1 TUG1
2 melanoma 31.0 H19 HOTAIR MALAT1 MEG3 MIR100 MIR137
3 retinoblastoma 30.9 CCAT1 HOTAIR MALAT1 MEG3
4 esophageal cancer 30.7 CCAT1 H19 HOTAIR MALAT1 MEG3 MIR21
5 tongue squamous cell carcinoma 30.6 MALAT1 MEG3 MIR21 UCA1
6 hepatocellular carcinoma 30.3 CCAT1 CCAT2 H19 HOTAIR MALAT1 MEG3
7 ovarian cancer 30.3 CCAT1 CCAT2 H19 HOTAIR MALAT1 MEG3
8 breast cancer 30.2 CCAT1 CCAT2 FOXCUT H19 HOTAIR MALAT1
9 leukoplakia 10.8
10 oral leukoplakia 10.7
11 lichen planus 10.6
12 oral lichen planus 10.6
13 oral submucous fibrosis 10.6
14 triple-receptor negative breast cancer 10.6 HOTAIR MALAT1
15 hypoxia 10.6
16 pancreatic ductal adenocarcinoma 10.6 H19 HOTAIR MALAT1 MIR21 UCA1
17 functionless pituitary adenoma 10.6 HOTAIR MEG3
18 small cell cancer of the lung 10.6 CCAT2 HOTAIR MALAT1 MIR21 TUG1
19 ovarian epithelial cancer 10.6 H19 HOTAIR MALAT1 MEG3
20 thyroid cancer 10.6 H19 HOTAIR MALAT1 UCA1
21 gastric cardia adenocarcinoma 10.6 H19 HOTAIR MEG3
22 laryngeal squamous cell carcinoma 10.5 CCAT1 H19 HOTAIR MALAT1 MIR21
23 malignant glioma 10.5 CCAT1 HOTAIR TUG1
24 cholangiocarcinoma 10.5 CCAT2 H19 MALAT1 MIR21 TUG1 UCA1
25 pituitary adenoma 10.5 CCAT2 H19 HOTAIR MALAT1 MEG3
26 esophagus squamous cell carcinoma 10.5 HOTAIR MEG3
27 kidney cancer 10.5 H19 HOTAIR MALAT1 MEG3 MIR21
28 squamous cell papilloma 10.5
29 papilloma 10.5
30 thyroid cancer, nonmedullary, 1 10.5 H19 HOTAIR MALAT1 MEG3
31 bladder urothelial carcinoma 10.5 HOTAIR MALAT1 MEG3 TUG1
32 clear cell renal cell carcinoma 10.5 CCAT2 MALAT1 MEG3 MIR21 TUG1
33 pre-eclampsia 10.5 H19 HOTAIR MALAT1 TUG1
34 gastrointestinal system cancer 10.5 H19 HOTAIR MALAT1
35 renal cell carcinoma, nonpapillary 10.5 CCAT1 H19 HOTAIR MALAT1 TUG1 UCA1
36 glioblastoma 10.5 H19 HOTAIR MALAT1 MEG3 MIR137 MIR21
37 ovarian serous carcinoma 10.5 MIR100 MIR21
38 leukemia, chronic myeloid 10.5 H19 HOTAIR MEG3 UCA1
39 intrahepatic cholangiocarcinoma 10.5 CCAT1 CCAT2 TUG1
40 leukemia, acute myeloid 10.5 CCAT1 HOTAIR MALAT1 MEG3 MIR21 TUG1
41 gallbladder cancer 10.5 CCAT1 H19 HOTAIR MALAT1 MEG3 TUG1
42 myeloma, multiple 10.5 CCAT1 H19 HOTAIR MALAT1 MEG3 TUG1
43 vulva squamous cell carcinoma 10.4 MALAT1 MEG3
44 lung cancer susceptibility 3 10.4 CCAT1 H19 HOTAIR MALAT1 MEG3 TUG1
45 astrocytoma 10.4 H19 HOTAIR MIR21
46 prostate disease 10.4 H19 MALAT1 MEG3
47 hypereosinophilic syndrome 10.4
48 lung squamous cell carcinoma 10.4 CCAT1 CCAT2 MEG3 TUG1
49 osteogenic sarcoma 10.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 MEG3
50 adamantinoma of long bones 10.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 MEG3

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

About this section
Sources

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

About this section

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
2
Pentetic acid Approved Phase 4 67-43-6
3 Omega 3 Fatty Acid Phase 4,Phase 2
4 arginine Phase 4,Phase 2
5 Technetium Tc 99m Sulfur Colloid Phase 4,Not Applicable
6 Anticoagulants Phase 4
7 Radiopharmaceuticals Phase 4,Not Applicable
8 Blood Substitutes Phase 4
9 Plasma Substitutes Phase 4
10 Dextrans Phase 4
11 Technetium Tc 99m Pentetate Phase 4
12 Chelating Agents Phase 4
13
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
14
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
16
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
17
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
18
Pilocarpine Approved, Investigational Phase 3 54-71-7, 92-13-7 5910
19
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
20
Metformin Approved Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
21
Durvalumab Approved, Investigational Phase 2, Phase 3,Phase 1 1428935-60-7
22
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
23
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
24
Zinc Approved, Investigational Phase 3,Phase 2 7440-66-6 32051
25
Indomethacin Approved, Investigational Phase 3,Phase 2 53-86-1 3715
26
Bevacizumab Approved, Investigational Phase 3 216974-75-3
27 Kava Approved, Investigational, Nutraceutical Phase 3,Phase 2 9000-38-8
28 Antimetabolites Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
32 Antiviral Agents Phase 3,Phase 2,Early Phase 1
33 Anti-HIV Agents Phase 3,Phase 2
34 Anti-Retroviral Agents Phase 3,Phase 2
35 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
36 Interleukin-2 Phase 3
37 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
38 Peripheral Nervous System Agents Phase 3,Phase 2,Early Phase 1
39 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1
40 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
41 Antibodies Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
42 Cyclooxygenase Inhibitors Phase 3,Phase 2
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1
44 Analgesics Phase 3,Phase 2
45 Analgesics, Non-Narcotic Phase 3,Phase 2
46 Anti-Inflammatory Agents Phase 3,Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
48 Mitogens Phase 3,Phase 2,Phase 1
49 Vaccines Phase 3,Phase 2
50 Muscarinic Agonists Phase 3

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
2 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
3 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
4 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
5 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
6 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
7 TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
8 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
9 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
10 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
11 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3 pilocarpine hydrochloride
12 Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
13 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
14 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
15 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
16 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Active, not recruiting NCT01265849 Phase 3 Cyclophosphamide;Indomethacin;Cisplatin
17 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
18 Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Unknown status NCT02739204 Phase 2 Celecoxib
19 Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Unknown status NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
20 Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer Unknown status NCT00566540 Phase 2 Cisplatin;Paclitaxel
21 A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
22 Efficacy of Purslane in Treatment of Oral Lichen Planus Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
23 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
24 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed NCT01553851 Phase 2 GSK1120212
25 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2 cisplatin
26 TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Completed NCT01108042 Phase 1, Phase 2 Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
27 A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer Completed NCT01314755 Phase 2
28 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
29 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
30 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
31 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
32 Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma Recruiting NCT03502148 Phase 1, Phase 2 PRV111 (Cisplatin Transmucosal System)
33 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
34 Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage Recruiting NCT02290145 Phase 2 TPF group
35 GDF15 Based TPF Induction Chemotherapy for OSCC Patients Recruiting NCT02285530 Phase 2 TPF induction chemotherapy
36 Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT03784066 Phase 1, Phase 2 Durvalumab
37 Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02873819 Phase 2 GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo
38 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02919683 Phase 2 Nivolumab;Ipilimumab
39 Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer Recruiting NCT03090412 Phase 2 HPPH;Photodynamic Therapy
40 ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment Recruiting NCT02917629 Phase 2 Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
41 Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting NCT03021993 Phase 2 Nivolumab
42 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Recruiting NCT03515538 Phase 2 RRx-001;Cisplatin for injection
43 A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02207439 Phase 2 Nelfinavir (Viracept®) 1250 mg;FMISO
44 Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. Recruiting NCT02882308 Phase 2 Olaparib;Cisplatin;Olaparib;Durvalumab
45 Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma Recruiting NCT02949700 Phase 1, Phase 2 Metformin
46 De-Intensification Radiotherapy Postoperative Head Neck Recruiting NCT02528955 Phase 2
47 Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma Recruiting NCT02384434 Phase 1, Phase 2
48 Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases Recruiting NCT02106598 Phase 1, Phase 2 fluorescent cRGDY-PEG-Cy5.5-C dots
49 Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Recruiting NCT03854032 Phase 2
50 Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting NCT02827838 Phase 2

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Sources

Genetic Tests for Oral Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Oral Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

42
Lymph Node, Endothelial, Bone, Skin, T Cells, Tongue, Neutrophil
Sources

Publications for Oral Squamous Cell Carcinoma

About this section

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 3923)
# Title Authors Year
1
Vascular density and inflammatory infiltrate in primary oral squamous cell carcinoma and after allogeneic hematopoietic stem cell transplantation. ( 30519712 )
2019
2
Evaluation of salivary metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 30714209 )
2019
3
Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma. ( 30842161 )
2019
4
Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study. ( 30857448 )
2019
5
"Expression of p16 in oral leukoplakia and oral squamous cell carcinoma and correlation of its expression with individual atypical features". ( 30963022 )
2019
6
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. ( 31027907 )
2019
7
Identification of Candida albicans using different culture media and its association in leukoplakia and oral squamous cell carcinoma. ( 31110413 )
2019
8
Immunohistochemical study of α-smooth muscle actin expression in oral leukoplakia and oral squamous cell carcinoma. ( 31110418 )
2019
9
An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation. ( 31110440 )
2019
10
Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus. ( 30964915 )
2019
11
Oral lichen planus and other confounding factors in narrow band imaging (NBI) during routine inspection of oral cavity for early detection of oral squamous cell carcinoma: a retrospective pilot study. ( 31039762 )
2019
12
The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis. ( 31093793 )
2019
13
Effect of Topical Application of Pure Honey in Chemo-radiation-Induced Mucositis and Its Clinical Benefits in Improving Quality of Life in Patients of Oral Squamous Cell Carcinoma. ( 30728696 )
2019
14
The Elental® elemental diet for chemoradiotherapy-induced oral mucositis: A prospective study in patients with oral squamous cell carcinoma. ( 30655992 )
2019
15
The Oncogenic Activity of miR-29b-1-5p Induces the Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma. ( 30813466 )
2019
16
Establishment and characterization of novel human oral squamous cell carcinoma cell lines from advanced‑stage tumors of buccal mucosa. ( 30816493 )
2019
17
Changes in the expression of the potassium channels TASK1, TASK3 and TRESK in a rat model of oral squamous cell carcinoma and their relation to malignancy. ( 30818127 )
2019
18
Evaluation of metastasis and 5-year survival in oral squamous cell carcinoma patients in Isfahan (2001-2015). ( 30820206 )
2019
19
Is Lymph Node Ratio a Prognostic Factor for Patients With Oral Squamous Cell Carcinoma? ( 30822404 )
2019
20
Selective Neck Dissection and Survival in Pathologically Node-Positive Oral Squamous Cell Carcinoma. ( 30823588 )
2019
21
The Novel Capsazepine Analog, CIDD-99, Significantly Inhibits Oral Squamous Cell Carcinoma In Vivo Through a TRPV1-Independent Induction of ER Stress, Mitochondrial Dysfunction, and Apoptosis. ( 30825343 )
2019
22
5-Aza-CdR promotes partial MGMT demethylation and modifies expression of different genes in oral squamous cell carcinoma. ( 30827853 )
2019
23
Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma. ( 30831033 )
2019
24
Low prevalence of HPV-induced oral squamous cell carcinoma in Geneva, Switzerland. ( 30839148 )
2019
25
Induced Pluripotent Stem Cell-related Genes Correlate With Poor Prognoses of Oral Squamous Cell Carcinoma. ( 30842151 )
2019
26
HSF1 in cancer-associated fibroblasts is a potential prognostic factor and drives progression of oral squamous cell carcinoma. ( 30843645 )
2019
27
Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro. ( 30846168 )
2019
28
Elective neck dissection in oral squamous cell carcinoma: Past, present and future. ( 30846183 )
2019
29
Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition. ( 30854080 )
2019
30
Circular RNA hsa_circ_0055538 regulates the malignant biological behavior of oral squamous cell carcinoma through the p53/Bcl-2/caspase signaling pathway. ( 30857544 )
2019
31
Identification of key pathways regulated by a set of competitive long non-coding RNAs in oral squamous cell carcinoma. ( 30862271 )
2019
32
p53-positive expression in dysplastic surgical margins is a predictor of tumor recurrence in patients with early oral squamous cell carcinoma. ( 30863157 )
2019
33
Novel K6-K14 keratin fusion enhances cancer stemness and aggressiveness in oral squamous cell carcinoma. ( 30867567 )
2019
34
Long non-coding RNA CRNDE regulates cell proliferation, migration, invasion, epithelial-mesenchymal transition and apoptosis in oral squamous cell carcinoma. ( 30867767 )
2019
35
Serum miR-626 and miR-5100 are Promising Prognosis Predictors for Oral Squamous Cell Carcinoma. ( 30867806 )
2019
36
Long-Term Exposure to Oroxylin A Inhibits Metastasis by Suppressing CCL2 in Oral Squamous Cell Carcinoma Cells. ( 30871117 )
2019
37
Estimation of serum matrix metalloproteinases among patients of oral squamous cell carcinoma. ( 30881433 )
2019
38
MiR-223 promotes oral squamous cell carcinoma proliferation and migration by regulating FBXW7. ( 30883339 )
2019
39
Taiwanin C elicits apoptosis in arecoline and 4-nitroquinoline-1-oxide-induced oral squamous cell carcinoma cells and hinders proliferation via epidermal growth factor receptor/PI3K suppression. ( 30884126 )
2019
40
Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study. ( 30887897 )
2019
41
TNF-α-induced miR-450a mediates TMEM182 expression to promote oral squamous cell carcinoma motility. ( 30893332 )
2019
42
CLIC1 promotes the progression of oral squamous cell carcinoma via integrins/ERK pathways. ( 30899362 )
2019
43
Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma. ( 30900666 )
2019
44
A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy. ( 30907457 )
2019
45
Increased salivary microvesicles are associated with the prognosis of patients with oral squamous cell carcinoma. ( 30907490 )
2019
46
Decreased expression of hsa_circ_0072387 as a valuable predictor for oral squamous cell carcinoma. ( 30908839 )
2019
47
Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway. ( 30909080 )
2019
48
Assessment of Factors Affecting Quality of Life in Oral Squamous Cell Carcinoma Patients Using University of Washington Quality of Life Questionnaire. ( 30911459 )
2019
49
Activin A regulates the epidermal growth factor receptor promoter by activating the PI3K/SP1 pathway in oral squamous cell carcinoma cells. ( 30914776 )
2019
50
A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients. ( 30917536 )
2019
Sources

Variations for Oral Squamous Cell Carcinoma

About this section

Cosmic variations for Oral Squamous Cell Carcinoma:

9 (show top 50) (show all 1145)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 19:30445497-30445497 0
2 COSM6976115 YES1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1288C>T p.Q430* 18:736811-736811 0
3 COSM6914703 XPO1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.619C>G p.Q207E 2:61498885-61498885 0
4 COSM6957917 TSC2 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1120A>T p.T374S 16:2061871-2061871 0
5 COSM121050 TP63 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.551C>T p.S184L 3:189808498-189808498 0
6 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
7 COSM69404 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 0
8 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
9 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
10 COSM11244 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>A p.I255N 17:7674199-7674199 0
11 COSM44233 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.840A>C p.R280S 17:7673780-7673780 0
12 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 17:7673823-7673823 0
13 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 17:7674229-7674229 0
14 COSM43850 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>C p.Y220S 17:7674872-7674872 0
15 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 0
16 COSM10786 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 17:7673579-7673579 0
17 COSM10943 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.841G>C p.D281H 17:7673779-7673779 0
18 COSM11354 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.991C>T p.Q331* 17:7673537-7673537 0
19 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
20 COSM11084 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>A p.V173M 17:7675095-7675095 0
21 COSM43665 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 0
22 COSM44351 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.572C>T p.P191L 17:7674959-7674959 0
23 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 17:7673704-7673704 0
24 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 17:7673793-7673793 0
25 COSM45618 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.931A>C p.N311H 17:7673597-7673597 0
26 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 17:7674215-7674215 0
27 COSM44229 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.515T>A p.V172D 17:7675097-7675097 0
28 COSM10725 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 0
29 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
30 COSM10771 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.749C>T p.P250L 17:7674214-7674214 0
31 COSM10939 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 0
32 COSM44633 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.583A>T p.I195F 17:7674948-7674948 0
33 COSM45353 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673G>A p.V225I 17:7674290-7674290 0
34 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 0
35 COSM44935 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.724T>A p.C242S 17:7674239-7674239 0
36 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
37 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 17:7673784-7673784 0
38 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
39 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
40 COSM10735 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.638G>A p.R213Q 17:7674893-7674893 0
41 COSM44823 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.981T>G p.Y327* 17:7673547-7673547 0
42 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 17:7673781-7673781 0
43 COSM43559 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>T p.V173L 17:7675095-7675095 0
44 COSM43680 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.523C>T p.R175C 17:7675089-7675089 0
45 COSM43906 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.843C>A p.D281E 17:7673777-7673777 0
46 COSM10863 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.833C>T p.P278L 17:7673787-7673787 0
47 COSM43772 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.538G>A p.E180K 17:7675074-7675074 0
48 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
49 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 17:7673799-7673799 0
50 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 17:7673781-7673781 0

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification EMS1 Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification TAOS1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification ORAOV1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma
Sources

Expression for Oral Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.
Sources

Pathways for Oral Squamous Cell Carcinoma

About this section

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
LncRNA-mediated mechanisms of therapeutic resistance 1
9.88 HOTAIR MEG3 UCA1
Sources

GO Terms for Oral Squamous Cell Carcinoma

About this section

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MEG3 MIR100 MIR137 MIR193A MIR21

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.33 MIR137 MIR193A MIR21
2 negative regulation of blood vessel endothelial cell migration GO:0043537 9.32 MIR137 MIR193A
3 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.26 MIR137 MIR21
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.13 MIR137 MIR193A MIR21
5 gene silencing by miRNA GO:0035195 9.1 H19 MEG3 MIR100 MIR137 MIR193A MIR21
Sources

Sources for Oral Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....